Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 1/20 | 0.57 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.57 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.57 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.57 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.57 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 9/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.52 |
| ▸ | CDC25B | P30305 | 5/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.48 |
| ▸ | TACR2 | P21452 | 2/20 | 0.48 |
| ▸ | GJB2 | P29033 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16327883 | 1.00 | SSTR1 (0.57) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL10623502 | 0.99 | SSTR1 (0.56) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL19731783 | 0.99 | SSTR1 (0.59) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL22584998 | 0.97 | SSTR1 (0.59) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL22678415 | 0.94 | SSTR1 (0.57) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL22677692 | 0.94 | SSTR1 (0.57) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL22677699 | 0.94 | SSTR1 (0.57) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL8991992 | 0.93 | SSTR1 (0.59) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL8991995 | 0.93 | SSTR1 (0.59) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL24371822 | 0.93 | NT5E (0.60) | SSTR1SSTR2SSTR4SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144655-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144655-A1 | ORGANIC COMPOUNDS | OAT, MAVS, HAVCR2 | SSTR1 4675/4885SSTR2 4566/4885SSTR4 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.